-
-
-
-
-
-
-
Verastem presents two-year follow-up data for ovarian cancer therapy
-
-
-
-
-
-
-
H.C. Wainwright Assumes Verastem (VSTM) at Buy
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Verastem (VSTM) on Dual-Program Growth Potential
-
-
-
-
-
-
-
Verastem gets fast track status for pancreatic cancer drug VS-7375
-
-
-
-
-
-
-
Verastem Oncology (VSTM) announces positive results from phase 1/2 trial on Avutometinib plus Defactinib
-
-
-
-
-
-
-
Verastem Oncology (VSTM) Announces U.S. IND Clearance of VS-7375
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Verastem (VSTM)
-
415,737 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

